MedTrace Logo

Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang

NCT06912035 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-04-04

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if diacerein supplementation can help improve inflammation and glycemic control in adults with uncontrolled type 2 diabetes. It will also study the safety and tolerability of diacerein. The main questions it aims to answer are:

* Does diacerein lower levels of inflammatory markers like interleukin-1β, hs-CRP, and TNF-α?
* Does diacerein improve blood sugar control?
* What side effects or problems do participants have when taking diacerein?

Researchers will compare diacerein to a placebo (a look-alike substance with no active drug) to see if it works better for managing type 2 diabetes.

Participants will:

* Be adults aged 40-60 with uncontrolled type 2 diabetes
* Take either diacerein or a placebo every day for 12 weeks
* Visit the clinic for blood tests and monitoring at the beginning and end of the trial
* Be evaluated for side effects and medication adherence\]

Conditions

  • Uncontrolled Diabetes
  • Diabetes Mellitus Type 2

Interventions

DRUG

Diacerein 50 mg Capsule

The patients received diacerein capsules

DRUG

Placebo

Patients received placebo capsules

Sponsors & Collaborators

  • Indonesia Endowment Fund for Education (LPDP), Ministry of Finance Republik of Indonesia

    collaborator UNKNOWN

  • Universitas Sriwijaya

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2024-11-08
Completion
2024-11-08

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06912035 on ClinicalTrials.gov